What is Chlophedianol?
Chlophedianol (also spelled clofedanol) is a centrally-acting, non-narcotic cough suppressant (antitussive) that works by suppressing the cough reflex in the brain. 1
Pharmacological Classification
Chlophedianol hydrochloride is classified as a centrally-acting antitussive agent that operates through central nervous system mechanisms to reduce cough, similar to codeine but without opioid properties 2. It is FDA-approved and available in over-the-counter formulations, often combined with antihistamines such as dexbrompheniramine maleate 1.
Mechanism and Efficacy
The drug acts centrally to suppress the cough reflex without causing respiratory depression, distinguishing it from narcotic antitussives 2. In comparative studies, chlophedianol (20 mg) demonstrated equivalent efficacy to other centrally-acting antitussives in suppressing cough associated with respiratory tract infections, as measured by both 3-hour and 24-hour cough counts 2.
Clinical Context
While chlophedianol is mentioned among FDA-approved OTC antitussives for acute cough due to upper respiratory infections, the evidence supporting its efficacy specifically in pediatric URI-associated cough is notably absent 3. This lack of contemporary, well-designed research is a common limitation across many OTC cough suppressants available in the United States.
Dosing and Formulation
The typical formulation contains 12.5 mg of chlophedianol hydrochloride per 5 mL (teaspoonful), often combined with 1 mg dexbrompheniramine maleate as an antihistamine 1. Standard dosing in clinical trials has been 20 mg three times daily 2.
Safety Profile
Chlophedianol has demonstrated a relatively favorable safety profile with few, mild side effects that typically do not require dose reduction or treatment discontinuation 2. The drug does not interfere with the expectoration process, allowing productive cough mechanisms to remain intact when needed 2.
Important Caveat
Chlophedianol is not mentioned in major clinical practice guidelines for cough management, such as the 2017 CHEST guidelines for lung cancer-associated cough 4, suggesting its role may be limited to self-limited, acute cough from upper respiratory infections rather than chronic or pathological cough conditions.